Jonathan Symonds Acquires 1,500 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Jonathan Symonds bought 1,500 shares of the company’s stock in a transaction on Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, with a total value of £28,215.

GSK Price Performance

Shares of LON:GSK traded down GBX 2.50 during trading on Tuesday, hitting GBX 1,908.50. 1,767,880,500 shares of the stock were exchanged, compared to its average volume of 22,712,896. The company has a fifty day moving average price of GBX 1,890.22 and a two-hundred day moving average price of GBX 1,953.51. The company has a market cap of £76.47 billion, a PE ratio of 16.20, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK plc has a 12-month low of GBX 1,455 and a 12-month high of GBX 2,282.

GSK (LON:GSK) last posted its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, analysts forecast that GSK plc will post 175.980975 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on GSK shares. Berenberg Bank lifted their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday, September 15th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Wednesday, July 29th. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a research report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Tuesday, September 15th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.